Patient-Reported Outcomes and Endoscopic Appearance of Ulcerative Colitis-a Systematic Review and Meta-Analysis.

Patient-Reported Outcomes and Endoscopic Appearance of Ulcerative Colitis-a Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2018 Jun 15;: Authors: Narula N, Alshahrani AA, Yuan Y, Reinisch W, Colombel JF Abstract BACKGROUND & AIMS: We aimed to evaluate the association of the patient-reported outcomes for rectal bleeding and stool frequency among patients with ulcerative colitis (UC) in endoscopic remission. METHODS: We performed a systematic review of studies reporting the association of patient-reported outcomes (the patient-reported components of the Mayo score: rectal bleeding and stool frequency) and endoscopic remission (Mayo endoscopic subscore…

Read More

Increased Risk of Herpes Zoster Infection in Patients with Inflammatory Bowel Diseases in Korea.

Increased Risk of Herpes Zoster Infection in Patients with Inflammatory Bowel Diseases in Korea. Clin Gastroenterol Hepatol. 2018 May 29;: Authors: Chang K, Lee HS, Kim YJ, Kim SO, Kim SH, Lee SH, Song EM, Hwang SW, Park SH, Yang DH, Ye BD, Byeon JS, Myung SJ, Yang SK Abstract BACKGROUND & AIMS: Few data are available on risk of herpes zoster (HZ) infection in Asian patients with inflammatory bowel diseases (IBD). We investigated whether patients with IBD in Korea have an increased risk of HZ and sought to identify…

Read More

Rapid response to vedolizumab therapy in biologic-naïve patients with inflammatory bowel diseases.

Rapid response to vedolizumab therapy in biologic-naïve patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2018 May 29;: Authors: Feagan BG, Lasch K, Lissoos T, Cao C, Wojtowicz AM, Khalid JM, Colombel JF Abstract BACKGROUND & AIMS: Vedolizumab, a humanized monoclonal antibody against α4β7 integrin, is used to treat adults with moderately to severely active ulcerative colitis (UC) and Crohn’s disease (CD). We investigated the time course of clinical response to vedolizumab in patients who were and were not previously treated with tumor necrosis factor (TNF) antagonists. METHODS: We performed…

Read More

Analysis of DNA Methylation at Specific Loci in Stool Samples Detects Colorectal Cancer and High-grade Dysplasia in Patients with Inflammatory Bowel Disease.

Analysis of DNA Methylation at Specific Loci in Stool Samples Detects Colorectal Cancer and High-grade Dysplasia in Patients with Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2018 May 15;: Authors: Kisiel JB, Klepp P, Allawi HT, Taylor WR, Giakoumopoulos M, Sander T, Yab TC, Moum BA, Lidgard GP, Brackmann S, Mahoney DW, Roseth A, Ahlquist DA Abstract BACKGROUND & AIMS: Patients with inflammatory bowel diseases (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD), are at increased risk for colorectal cancer (CRC). Analyses of DNA methylation patterns in stool samples have…

Read More

Clinical Course of Nodular Regenerative Hyperplasia in Thiopurine Treated Inflammatory Bowel Disease Patients.

Clinical Course of Nodular Regenerative Hyperplasia in Thiopurine Treated Inflammatory Bowel Disease Patients. Clin Gastroenterol Hepatol. 2018 May 15;: Authors: Simsek M, Meijer B, Ramsoekh D, Bouma G, van der Wouden EJ, den Hartog B, de Vries AC, Hoentjen F, Dijkstra G, de Boer SY, Jansen JM, van der Meulen AE, Beukers R, Brink MA, Steinhauser T, Oldenburg B, Gilissen LP, Naber TH, Verhagen MA, de Boer NKH, Mulder CJJ, Dutch Initiative on Crohn and Colitis (ICC) PMID: 29775790 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/29775790?dopt=Abstract

Read More

Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease.

Related Articles Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2018 May 08;: Authors: Christensen B, Gibson P, Micic D, Colman RJ, Goeppinger SR, Kassim O, Yarur A, Weber CR, Cohen RD, Rubin DT Abstract BACKGROUND & AIMS: Little is known about the efficacy and safety of induction therapy with calcineurin inhibitors in combination with vedolizumab for patients with Crohn’s disease (CD) or ulcerative colitis (UC). We analyzed the outcomes of patients receiving vedolizumab along with calcineurin…

Read More

No Association Between Consumption of Sweetened Beverages and Later Risk of Crohn’s Disease or Ulcerative Colitis.

Related Articles No Association Between Consumption of Sweetened Beverages and Later Risk of Crohn’s Disease or Ulcerative Colitis. Clin Gastroenterol Hepatol. 2018 May 08;: Authors: Khalili H, Hakansson N, Chan SS, Ludvigsson JF, Olen O, Chan AT, Hart AR, Wolk A Abstract BACKGROUND & AIMS: Consumption of sweetened beverages has been associated with inflammation, based on measurements of C-reactive protein and tumor necrosis factor, as well as immune-mediated disorders including rheumatoid arthritis. We investigated associations with Crohn’s disease (CD) or ulcerative colitis (UC). METHODS: We conducted a prospective cohort study…

Read More
<< Go Back